| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 83251 |
cas:186023-44-9 Fmoc-Ala-Pro-OH |
197 |
zyl |
2024-12-19 |
| 83252 |
TCO-PEG4-Val-Cit-PAB-PNP，反式环辛烯-四聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
152 |
WYQ |
2024-12-19 |
| 83253 |
Boc-Val-Cit CAS:870487-08-4 |
220 |
zyl |
2024-12-19 |
| 83254 |
DOTA-Bn-FGK-Fab DOTA标记抗体片段 |
170 |
h |
2024-12-19 |
| 83255 |
cas:252554-78-2，Fmoc-Ala-Ser (Psi(Me,Me)pro)-OH，(4S)-3-[(2S)-2-[[(9H-芴-9-甲氧基)羰基]氨基]-1-氧代丙基]-2,2-二甲基-4-恶唑烷羧酸 |
136 |
kx |
2024-12-19 |
| 83256 |
DOTA-Nal3-Octreotide DOTANOC DOTA-Nal3-奥曲肽 |
145 |
h |
2024-12-19 |
| 83257 |
cas:2413428-36-9，MC-Gly-Gly-Phe-Gly，(S)-5-苄基-18-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)-4,7,10,13-四氧代-3,6,9,12-四氮杂十八烷-1-酸 |
130 |
kx |
2024-12-19 |
| 83258 |
MC-Val-Cit-PAB-PNP CAS:159857-81-5 |
210 |
zyl |
2024-12-19 |
| 83259 |
cas:2353409-52-4，Mal-amido-PEG8-Val-Gly-PAB-OH，马来酰亚胺-酰胺-八聚乙二醇-VAL-GLY-PAB-羟基 |
105 |
kx |
2024-12-19 |
| 83260 |
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB CAS:2055042-69-6 |
122 |
zyl |
2024-12-19 |
| 83261 |
cas:1895916-22-9，MC-Val-Ala-OH， ADC试剂 |
129 |
kx |
2024-12-19 |
| 83262 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，MC-VAL-CIT-阿霉素 |
95 |
kx |
2024-12-19 |
| 83263 |
DOTA−Gal-NAPamide DOTA−Gal-纳帕胺 |
110 |
h |
2024-12-19 |
| 83264 |
DOTA-peptide-Lym-1 radioimmunotherapy DOTA-肽-Lym-1 |
134 |
h |
2024-12-19 |
| 83265 |
N-DBCO-N-bis(PEG2-amide-PEG4-Val-cit-PAB-MMAE)， N-二苯并环辛炔-N-双(二聚乙二醇-酰胺-四聚乙二醇-VAL-CIT-PAB-MMAE) |
152 |
kx |
2024-12-19 |
| 83266 |
DOTA-dGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 |
172 |
h |
2024-12-19 |
| 83267 |
DOTA-MGO DOTA-DGlu-(Glu)s-minigastrin |
118 |
h |
2024-12-19 |
| 83268 |
cas:2762518-86-3，NHS Ester-PEG4-Val-Cit-PAB-MMAE， ADC试剂 |
166 |
kx |
2024-12-19 |
| 83269 |
DOTA-scFv-anti-PSMA DOTA-scFv-抗PSMA脂质纳米粒(LNPs) |
150 |
h |
2024-12-19 |
| 83270 |
cas:2353409-45-5，BCN-PEG3-Val-Cit-PFP Ester， ADC试剂 |
132 |
kx |
2024-12-19 |
| 83271 |
cas:2112738-13-1，Mal-amido-PEG2-Val-Cit-PAB-PNP， ADC试剂 |
113 |
kx |
2024-12-19 |
| 83272 |
cas:2055041-39-7，Mal-PEG4-Val-Cit-PAB-OH， ADC试剂 |
161 |
kx |
2024-12-19 |
| 83273 |
cas:2055024-62-7，NH2-PEG3-Val-Cit-PAB-OH， ADC试剂 |
208 |
kx |
2024-12-19 |
| 83274 |
Fmoc-PEG3-Val-Cit，N-芴甲氧羰基-三聚乙二醇-VAL-CIT |
163 |
kx |
2024-12-19 |
| 83275 |
DOTA-anti-VLA-4 |
142 |
h |
2024-12-19 |
| 83276 |
DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide |
127 |
h |
2024-12-19 |
| 83277 |
CAS: 2748039-76-9， Alkyne-Val-Cit-PAB-FAM，炔-Val-Cit-PAB-FAM |
130 |
WYQ |
2024-12-19 |
| 83278 |
CAS:646502-53-6 MC-Val-Cit-PAB-MMAE的结构式 |
186 |
zyl |
2024-12-19 |
| 83279 |
Amino-PEG2-VG-N-Bis(PEG1-azide)，氨基-二聚乙二醇-VG-N-双（一聚乙二醇-叠氮） |
147 |
WYQ |
2024-12-19 |
| 83280 |
Azido-PEG8-Val-Cit-PAB-PNP，C34H47N9O12 |
133 |
WYQ |
2024-12-19 |
| 83281 |
化合物：TCO-MMAE，反式环辛烯-MMAE（其中MMAE为单甲基澳瑞他汀E的缩写） |
207 |
WYQ |
2024-12-19 |
| 83282 |
cas:2748039-77-0，Alkyne-Val-Cit-PAB-PNP，炔-VAL-CIT-PAB-PNP 酯 |
122 |
kx |
2024-12-19 |
| 83283 |
endo BCN-PEG3-Val-Cit，endo BCN-聚乙二醇3-缬氨酸-瓜氨酸，CAS号：1263166-91-1 |
179 |
WYQ |
2024-12-19 |
| 83284 |
cas:1803279-86-8，DBCO-C4-SulfoNHS ester， ADC试剂 |
111 |
kx |
2024-12-19 |
| 83285 |
Mal-PEG8-Val-Cit-PAB-MMAE CAS:2353409-69-3 |
154 |
zyl |
2024-12-19 |
| 83286 |
159857-80-4，MC-Val-Cit-PAB-OH，MC-VAL-CIT-PAB中间体 |
116 |
kx |
2024-12-19 |
| 83287 |
氨基-四聚乙二醇-Val-Cit-PAB-MMAE，Amino-PEG4-Val-Cit-PAB-MMAE，ADC定制 |
108 |
wyh |
2024-12-19 |
| 83288 |
CAS: 2748039-77-0，化合物：Alkyne-Val-Cit-PAB-PNP |
138 |
WYQ |
2024-12-19 |
| 83289 |
MAC glucuronide linker-2 CAS:229977-57-5 |
184 |
zyl |
2024-12-19 |
| 83290 |
DOTA-cPAM4 DOTA标记PAM4抗体 |
96 |
h |
2024-12-19 |
| 83291 |
PC SPDP-NHS carbonate ester， ADC试剂 |
194 |
kx |
2024-12-19 |
| 83292 |
Py-ds-Prp-OPFP的介绍 |
204 |
zyl |
2024-12-19 |
| 83293 |
cas:877864-04-5，THP-SS-alcohol， ADC试剂 |
111 |
kx |
2024-12-19 |
| 83294 |
MeO-DOTA−CC49 甲氧基DOTA偶联抗TAG-72单克隆抗体CC49 |
279 |
h |
2024-12-19 |
| 83295 |
Ala-Ala-Asn-PAB CAS:2149584-00-7 |
173 |
zyl |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询